Dr Lal PathLabs

November 8, 2019

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Press Release for Unaudited Financial Results (Standalone and Consolidated) for the Quarter & Half Year ended September 30, 2019

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter & Half Year ended September 30, 2019.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head

Encl: As above

For Immediate Release **November 8, 2019**

Dr. Lal PathLabs Limited records revenue growth of 15.1% to Rs 365.6 Cr in Q2 FY20

New Delhi, India, Nov 8, 2019 – Dr. Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2019

Consolidated Performance Highlights: Q2 FY20 vs Q2 FY19
Revenue growth: 15.1% at Rs 365.6 Cr,
Normalised EBITDA (excluding Ind AS 116) at Rs 104.7 Cr,
Normalised EBITDA margins (excluding Ind AS 116) at 28.6%,
PBT at Rs 102.3 Cr with margin at 28% and
PAT at Rs 81.0 Cr with margin at 22.2%

- Operating Revenue increased by 15.1% in Q2 FY 20 to Rs. 365.6 Cr vs Rs 317.5 Cr in the previous year same quarter. Underlying patient volume growth is 12.1% during the quarter
- Normalised EBITDA (after adjustment for stock based compensation, CSR cost & impact of Ind AS 116) for Q2 FY20 grew 15.7 % to Rs. 104.7 Cr from Rs 90.5 Cr in the same quarter last year
- Normalised EBITDA Margin ex Ind AS 116 at 28.6% for Q2 FY20
- PBT is at Rs 102.3 Cr in Q2 FY20 vs Rs 88.1 Cr. in Q2 last year, a growth of 16.1%
- Profit after Tax in Q2 FY20 at Rs. 81.0 Cr as compared to Rs 57.3 Cr in Q2 last year, a growth of 41.4%
- Interim Dividend of 60% i.e. Rs 6 per share has been approved by the Board of Directors of the company

Financial Overview (Consolidated) in Rs Cr

Particulars	Q2 FY20 (With IND-AS 116)	Q2 FY20 (W/O IND-AS 116)	Q2 FY19 (W/O IND-AS 116)	*Gr % (With IND-AS 116*	*Gr % (W/O IND-AS 116)*	FH FY20 (With IND-AS 116)	FH FY20 (W/O IND-AS 116)	FH FY19 (W/O IND-AS 116)	*Gr % (With IND-AS 116*	*Gr % (W/O IND-AS 116)*
Revenue	365.6	365.6	317.5	*15.1%*	*15.1%*	700.8	700.8	609.8	*14.9%*	*14.9%*
Expenditure	256.7	265.5	230.7			496.8	513.8	448.0		
EBITDA	108.9	100.1	86.8	*25.5%*	*15.3%*	204.0	187.0	161.8	*26.1%*	*15.6%*
Adj for Stock based comp. & CSR cost	4.6	4.6	3.7			8.5	8.5	8.0		
Normalised EBITDA	113.5	104.7	90.5	*25.4%*	*15.7%*	212.5	195.5	169.8	*25.1%*	*15.1%*
Normalised Margins	*31.0%*	*28.6%*	*28.5%*			*30.3%*	*27.9%*	*27.8%*		
Other income incl. interest	14.8	14.8	10.9			29.2	29.2	20.3		
PBT	102.3	104.6	88.1	*16.1%*	*18.7%*	191.7	196.5	163.5	*17.2%*	*20.2%*
Margins	*28.0%*	*28.6%*	*27.7%*			*27.4%*	*28.0%*	*26.8%*		
PAT	81.0	82.9	57.3	*41.4%*	*44.7%*	140.1	143.6	107.0	*30.9%*	*34.2%*
Margins	*22.2%*	*22.7%*	*18.0%*			*20.0%*	*20.5%*	*17.5%*		
EPS (Basic)	9.77		6.91	*41.4%*		16.91		12.91	*30.9%*	
EPS (Diluted)	9.75		6.90	*41.3%*		16.86		12.89	*30.8%*	

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2019 the company has 200 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 2,569 Patient Service Centers (PSCs) and 6,426 Pick-up Points (PUPs). It's customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel
Chief Financial Officer
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Mittali Bharti
Adfactors PR

+91 9871154558
mittali.bharti@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.